Cyril Meillon1, Pierre Henry Gabrielle1, Maxime Luu2, Ludwig S Aho-Glele3, Alain M Bron4,5, Catherine Creuzot-Garcher1,6. 1. Department of Ophthalmology, University Hospital, 14 rue Paul Gaffarel, 21079, Dijon, France. 2. Plurithematic Clinical Investigation Center (CIC-P) INSERM 803 and Department of Medical Pharmacology, University Hospital, Dijon, France. 3. Hospital Hygiene and Epidemiology Unit, University Hospital, Dijon, France. 4. Department of Ophthalmology, University Hospital, 14 rue Paul Gaffarel, 21079, Dijon, France. alain.bron@chu-dijon.fr. 5. Eye and Nutrition Research Group, CSGA, UMR 1324 INRA, 6265 CNRS, University of Burgundy, Dijon, France. alain.bron@chu-dijon.fr. 6. Eye and Nutrition Research Group, CSGA, UMR 1324 INRA, 6265 CNRS, University of Burgundy, Dijon, France.
Abstract
PURPOSE: To assess the rate of hemorrhagic complications after vitreoretinal surgery and the influence of antithrombotic agents. METHODS: Hemorrhagic complications of vitreoretinal procedures performed in seven ophthalmologic centers on patients treated or not treated with antiplatelet (AP) or anticoagulant (AC) agents were prospectively collected. Patients' characteristics, surgical techniques, and complications were recorded during surgery and for 1 month after. RESULTS: Eight hundred four procedures were performed between January 2015 and April 2015. Among them, 18.4% were treated with AP agents (n = 148) and 7.8% with AC agents (n = 63), with 18 of them treated with NOACS (new oral anticoagulants). AP or AC agents were continued in 96.5% and 80.7% of cases, respectively. Fifty-three patients (6.6%) developed one or more hemorrhagic complications in one eye during this period. In univariate analysis, AC agents were not associated with hemorrhagic complications (P = 0.329) in contrast to AP (P = 0.005). However, in multivariate analysis, AP agents were no longer associated with hemorrhagic complications and the intraoperative use of endodiathermy was the only factor associated with hemorrhagic complications (P = 0.001). CONCLUSIONS: This study showed that AP and AC agents were not a factor associated with hemorrhagic complications during vitreoretinal surgery. The continuation of these treatments should be considered without risk of severe hemorrhagic complications.
PURPOSE: To assess the rate of hemorrhagic complications after vitreoretinal surgery and the influence of antithrombotic agents. METHODS:Hemorrhagic complications of vitreoretinal procedures performed in seven ophthalmologic centers on patients treated or not treated with antiplatelet (AP) or anticoagulant (AC) agents were prospectively collected. Patients' characteristics, surgical techniques, and complications were recorded during surgery and for 1 month after. RESULTS: Eight hundred four procedures were performed between January 2015 and April 2015. Among them, 18.4% were treated with AP agents (n = 148) and 7.8% with AC agents (n = 63), with 18 of them treated with NOACS (new oral anticoagulants). AP or AC agents were continued in 96.5% and 80.7% of cases, respectively. Fifty-three patients (6.6%) developed one or more hemorrhagic complications in one eye during this period. In univariate analysis, AC agents were not associated with hemorrhagic complications (P = 0.329) in contrast to AP (P = 0.005). However, in multivariate analysis, AP agents were no longer associated with hemorrhagic complications and the intraoperative use of endodiathermy was the only factor associated with hemorrhagic complications (P = 0.001). CONCLUSIONS: This study showed that AP and AC agents were not a factor associated with hemorrhagic complications during vitreoretinal surgery. The continuation of these treatments should be considered without risk of severe hemorrhagic complications.
Entities:
Keywords:
Anticoagulants; Antiplatelet agents; Antithrombotic therapy; Vitreoretinal surgery
Authors: N Feltgen; B Mele; T Dietlein; C Erb; A Eckstein; A Hager; A Heiligenhaus; H Helbig; H Hoerauf; E Hoffmann; D Pauleikhoff; M Schittkowski; B Seitz; C Sucker; S Suffo; U Schaudig; F Tost; S Thurau; P Walter; J Koscielny Journal: Ophthalmologe Date: 2018-07 Impact factor: 1.059
Authors: Peer Lauermann; Anthea Klingelhöfer; Dorothee Mielke; Dirk Bahlmann; Hans Hoerauf; Juergen Koscielny; Christoph Sucker; Nicolas Feltgen; Christian van Oterendorp Journal: Clin Ophthalmol Date: 2022-04-22